According to a recent LinkedIn post from Infinity Bio Inc, the company’s VP of Scientific Development, Katy Shaw-Saliba, is scheduled to present a scientific poster at the Keystone Symposia on Autoimmunity & Autoinflammation in March 2026. The poster, titled “Decoding the Antibody Reactome at Scale with Novel Antigen Display Technology to Decipher Immune History,” focuses on immune history and antibody profiling.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The company’s LinkedIn post highlights Infinity Bio’s involvement in cutting-edge immunology research and exposure at a specialized scientific conference. For investors, this visibility may signal ongoing R&D activity and potential to build partnerships or collaborations in translational research and biotechnology, though no commercial milestones or financial metrics are mentioned.
The post suggests Infinity Bio is positioning its antigen display technology as a tool for large-scale antibody and B-cell profiling, an area of interest for drug discovery and diagnostic development. If the underlying technology proves robust and attractive to researchers, it could support future licensing, platform deals, or co-development agreements, which may enhance the company’s long-term revenue potential.
As shared in the LinkedIn update, Infinity Bio appears focused on networking with researchers and collaborators at the event. For investors, this emphasis on scientific engagement and ecosystem building may be relevant to assessing the company’s pipeline maturation, partnership pipeline, and potential competitive standing within the broader immunology and translational research space.